Proving the potential success of biosimilars
The total cumulative export value of Remsima® reached KRW 1 trillion in 2016, which was a great achievement in the
biopharmaceutical history of Korea. In addition, Celltrion Healthcare managed to launch Remsima®® (Inflectra®) in the United
States, which is known for having the world’s top pharmaceutical market, and Truxima®, the world's first oncology
mAB biosimilar, in Europe, proving that biosimilars have the potential for success in the global markets.